TSBX 0.53 Turnstone Biologics Corp.
| Range: | 0.439-5.75 | Vol Avg: | 258168 | Last Div: | 0 | Changes: | 0.02 |
| Beta: | 0 | Cap: | 0.01B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Jul 21 2023 | Empoloyees: | 82 | ||
| CUSIP: | 90042W100 | CIK: | 0001764974 | ISIN: | US90042W1009 | Country: | US |
| CEO: | Dr. Sammy J. Farah M.B.A., Ph.D. | Website: | https://turnstonebio.com | ||||
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow